Poolbeg Pharma – Well Positioned for Success with CEO Jeremy Skillington

Poolbeg Pharma plc (LON:POLB) investor presentation with CEO Jeremy Skillington.

In this presentation Jeremy covers:

Company Overview and Strategic Position
Introduction to Poolbeg Pharma and its strategic positioning in the industry.
Overview of the leadership team and their expertise in building successful life science companies.

High Value Programmes for Partnering
Detailed information on key programs such as POLB 001, which targets cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and severe influenza.
Discussion on the market opportunities, the clinical development stages of various programs, and the company’s approach to partnerships.

Significant Progress Made in 2023
Summary of achievements in the past year including key milestones in AI-led drug discovery and strategic collaborations.
Discussion on the financial robustness of the company and its plans for future growth and value creation.

Scientific and Market Insights
Insights into the unmet needs in cancer treatment, specifically addressing CRS in cancer immunotherapies and the potential market for POLB 001.
Highlighting the strategic importance of the company’s programs in addressing these needs.

Product and Pipeline Development
Detailed breakdown of the clinical pipeline, including phase readiness of different therapeutic programs.
Explanation of the technologies and scientific approaches being used, such as oral delivery technologies and AI-led discovery programs.

Investor Considerations and Market Opportunity
Discussion on the financial health of the company and the significant market opportunities that lie ahead.
Outline of potential revenue streams from existing and future partnerships.

Leadership and Governance
Information on the executive team and board members, highlighting their roles and contributions to the company’s strategy.
Focus on the leadership’s background and their strategic vision for the company’s growth.

Click to view all articles for the EPIC:
Or click to view the full company profile:

More articles like this

GLP-1 receptor agonists transform diabetes treatment

GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a groundbreaking class of drugs in diabetes management, particularly due to their impressive efficacy in reducing obesity, a key factor in type 2 diabetes. Jeremy

AI revolutionising the pharmaceutical industry

The rapid advancement of artificial intelligence (AI) is making significant strides in the pharmaceutical sector. Since its inception, this industry has embraced AI and machine learning, continuing its legacy of innovation. The integration of these technologies

Poolbeg Pharma publishes Annual Report and AGM Notice

Poolbeg Pharma plc (LON: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has confirmed that the Company’s Annual Report and Accounts for the period ended

Poolbeg Pharma expands treatment into new markets

Poolbeg Pharma said it had made progress last year in expanding its treatments into new markets, with significant pipeline advancements and strategic deals. The company said it had made a strategic expansion into the treatment of

Poolbeg Pharma granted significant POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that, further to its announcement on 20 March 2024, the Company has received the fully granted

AI impact on biopharma business models

The culture of collaboration in the Pacific Northwest, the impact of AI on biopharma, and the shape of new business models driven by AI were all topics at a panel discussion Wednesday in Seattle at the

POLB 001: Targeting CRS in Cancer Immunotherapy

Phase 2 Ready orally administered p38 MAP Kinase inhibitor – a preventative therapy targeting an addressable market of more than $10 billion. POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer

Poolbeg Pharma updates on Immunomodulator II Patent

Poolbeg Pharma has announced that it has received a Notice of Allowance from the US Patent Office in relation to its Immunomodulator II patent application. A Notice of Allowance is a precursor to the expected formal grant